Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.66 |
| ▸ | RAB9A | P51151 | 6/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.50 |
| ▸ | GPR17 | Q13304 | 1/20 | 0.50 |
| ▸ | PLAU | P00749 | 2/20 | 0.49 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678733 | 0.86 | GRM5 (0.70) | GRM5RAB9ASMN1; SMN2NPC1MEN1 | |
| SCHEMBL1499498 | 0.80 | GRM5 (1.00) | GRM5RAB9ASMN1; SMN2TP53NPC1 | |
| SCHEMBL30136593 | 0.78 | KEAP1 (0.64) | GRM5RAB9A | |
| SCHEMBL761721 | 0.78 | KEAP1 (0.64) | GRM5RAB9A | |
| Hydrochloric Acid SCHEMBL28859534 | 0.77 | KEAP1 (0.62) | GRM5RAB9A | |
| SCHEMBL16339265 | 0.77 | GRM5 (0.64) | GRM5RAB9ASMN1; SMN2TP53NPC1 | |
| SCHEMBL3592038 | 0.77 | RAB9A (0.78) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL1818135 | 0.76 | ALDH1A1 (0.80) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL1813249 | 0.76 | RAB9A (0.81) | RAB9ASMN1; SMN2TP53NPC1MEN1 | |
| SCHEMBL6242208 | 0.75 | RAB9A (0.84) | RAB9ASMN1; SMN2TP53NPC1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS (US) | 2012-01-12 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-8003692-B2 | Methods and compositions to inhibit edema factor and adenylyl cyclase | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | MISSION PHARMACAL CO. (US) | 2009-04-09 | — | — | US | disclosed |
| WO-2009038842-A2 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | MISSION PHARMACAL CO. (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093519-A1 | Methods and Compositions to Inhibit Edema Factor and Adenylyl Cyclase | VIP, PDE3B, ADCY5 | GRM5 3638/4885RAB9A 1654/4885SMN1; SMN2 4854/4885 |
| US-20120010233-A1 | METHODS AND COMPOSITIONS TO INHIBIT EDEMA FACTOR AND ADENYLYL CYCLASE | VIP, PDE3B, ADCY5 | GRM5 3638/4885RAB9A 1654/4885SMN1; SMN2 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.